COVID-19 and MOG-IgG–associated acquired demyelinating polyneuropathy compatible with chronic inflammatory demyelinating polyneuropathy in a previously healthy girl

Akbar, Asra; Blume, Gregory; Creeden, Sean; Ahmad, Sharjeel

doi:10.1080/08998280.2022.2088466

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 19 patients were identified as positive for MOG IgG and for central and peripheral demyelination; 11 derived from single case reports (patients 9–22) [ 34 , 39 , 40 , 41 , 42 , 45 , 46 , 47 , 48 , 49 ] and 8 from two case series (patients 1–8) [ 37 , 38 ]. There were three cases of anti-MOG-positive demyelinating polyneuropathy without evidence of CNS involvement (patients 14–16) [ 43 , 44 ]. The first case report was published in 2018 (patient 9) [ 34 ].…”

Section: Resultsmentioning

confidence: 99%

“…Ten out of twenty-two (45%) patients had spinal cord lesions (patients 1, 3, 5, 8, 9, 10, 12, 13, 17, and 20) [ 34 , 37 , 38 , 39 , 42 , 45 , 48 ]. In two cases, patients presented with both ON and myelitis (patients 18 and 22) [ 46 , 49 ], while there were three cases with only PNS involvement without clear CNS involvement (neither myelitis nor ON) (patients 14–16) [ 43 , 44 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Combined Central and Peripheral Demyelination (CCPD) Associated with MOG Antibodies: Report of Four New Cases and Narrative Review of the Literature

Papadopoulou,

Tzanetakos,

Moschovos

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Myelin oligodendrocyte glycoprotein (MOG) is exclusively expressed in the central nervous system (CNS) and is found on the outer surface of oligodendrocytes. Antibodies to MOG are associated with CNS demyelination, whereas peripheral nervous system (PNS) demyelination is seldom reported to be related to MOG-IgG. Methods: The database of patients seen in our neurological academic center was searched for MOG-IgG seropositivity and concomitant demyelinating polyneuropathy. For the purpose of the review, in March 2024, we searched for case reports and case series in the following databases: PubMed, Scopus, Cochrane, and ScienceDirect. Inclusion criteria were MOG-IgG seropositivity and demyelinating polyneuropathy. Exclusion criteria were type of publication other than case reports and case series, unconfirmed diagnosis of demyelinating polyneuropathy, and other diseases causing demyelination in either the CNS or PNS. Critical appraisal of the selected case reports and case series was realized by JBI. Results: Four new cases were identified with MOG-IgG and confirmed demyelinating polyneuropathy. This review identified 22 cases that have been published since 2018. Clinical, imaging, neurophysiological, and immunological characteristics, as well as treatment options and outcomes are presented and compared to those of other cases with combined central and peripheral demyelination (CCPD). Conclusions: The pathogenetic mechanism is unclear; thus, different hypotheses are discussed. New case reporting and large cohort studies will help further the exploration of the underlying mechanism and guide more effective therapeutic interventions.

show abstract